

Global Cancer Vaccine Market, Vaccine Price, Dosage, Sales & Clinical Trials Outlook 2029

<https://marketpublishers.com/r/GEAD47ED7499EN.html>

Date: June 2023

Pages: 840

Price: US\$ 3,600.00 (Single User License)

ID: GEAD47ED7499EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Cancer Vaccine Market, Vaccine Price, Dosage, Sales & Clinical Trials Outlook 2029 Report Highlights:

Global Cancer Vaccine Market Opportunity : > USD 20 Billion By 2029

Cancer Vaccine Market Regional Trends Insight: 10 Countries

Cancer Vaccine Market Trends Insight By Indication: 10 Indications

Insight On Cancer Vaccine In Clinical Trials: > 400 Vaccines

Insight On Cancer Vaccine Commercially available in Market: > 15 Vaccines

Cancer Vaccines Clinical Trials By Company, Country, Indication & Phase

Approved Cancer Vaccines Price & Dosage Analysis

Proprietary Vaccine Manufacturing Technologies By Indication

In the era of modern medicine, innovative advancements are revolutionizing the field of cancer treatment. Among these innovative approaches are cancer vaccines which are emerging as a potential strategy that is offering transformation in the treatment of cancer. Harnessing the power of immune system, these vaccines hold the promise of

preventing, treating and ever eliminating various types of cancers. With the development of preventive as well as therapeutic cancer vaccines, it can be predicted that soon, cancer vaccines will hold a major share in the global cancer treatment market.

One of the most significant characteristics about cancer vaccines is their ability to provide personalized and precision medicine. Cancer vaccines can be customized to target specific antigens, mutations or signalling pathways present in a patient's tumor. By leveraging advancements in genomics and immunology, these vaccines offer a precise and targeted approach, maximizing treatment efficacy while minimizing adverse side effects.

To further enhance treatment outcomes, pharmaceutical companies have been investigating cancer vaccines in combination with other therapeutic modalities. By incorporating vaccines with immune checkpoint inhibitors, targeted therapies or chemotherapy, synergistic effects can be achieved, leading to improved response rates and long term remission. These combination approaches have demonstrated promising results in clinical trials, offering new possibilities for more effective and comprehensive cancer treatment regimes.

Furthermore, the development of cancer vaccines has been fueled by collaboration among pharmaceutical companies, research institutions and healthcare professionals. This collective effort has led to significant advancements in vaccine technology, formulation, optimization and clinical trial design and assessment. Additionally, with the support of government regulatory bodies and global health organizations, cancer vaccines have been progressing rapidly through the development of a robust clinical pipeline.

While cancer vaccines have shown promise in certain cancer types, the future holds a tremendous potential for expanding their application to a wider range of malignancies. Ongoing research is focused on developing vaccines for various solid tumors such as lung cancer, breast cancer, and ovarian cancer among several others. With each breakthrough, the spectrum of cancers that can be effectively treated or prevented with vaccines continues to expand.

As the field of cancer vaccines advances, efforts to ensure global access and collaboration will be a dominant factor. With ongoing research and development, the number of cancer vaccine candidates is increasing, targeting different types of cancers and utilizing various vaccine formulations. The period of COVID-19 determined the

importance of vaccines and how effective they can be in controlling disease progression. If same robust research continues towards cancer vaccine development, it can be predicted that not only preventive vaccines but also therapeutic vaccines will enter the global market.

In 2010, Dendreon launched Provenge, making history as it became the first ever therapeutic cancer vaccine. This cell based immunotherapy was targeted towards the treatment of prostate cancer. Achieving this milestone, the entry of Provenge encouraged the growth of other therapeutic cancer vaccines in clinical development. However, therapeutic vaccines have made great advancements in recent years and the products currently in clinical trials represent an era of low toxic treatment options while also addressing several unmet needs that continue in cancer.

Therapeutic cancer vaccines are poised to revolutionize cancer treatment by leveraging the power of immune system against cancer cells. As personalized, targeted therapies, they offer the potential for long lasting responses and improved patient outcomes. By combining these vaccines with other treatment modalities and expanding their reach to a broader range of cancers, researchers are currently paving the way for future where therapeutic cancer vaccines play a pivotal role in cancer treatment. With ongoing research and development, these vaccines will continue to expand the global cancer vaccine market.

Our report provides an in depth analysis about the current research and development landscape of cancer vaccines. Moreover, the report also provides pricing and dosage information about the currently approved preventive and therapeutic cancer vaccines. Apart from this, a regional analysis containing detailed overview about the countries and the intensity with which they are developing cancer vaccines. In addition, the report also provides information about the current market opportunities and the possible future prospects that might open in the global market of cancer vaccines.

Contents

1. INTRODUCTION TO CANCER VACCINES

2. MECHANISM OF CANCER VACCINES

- 2.1 Idiotypic Cancer Vaccine Mechanism
- 2.2 Cellular Cancer Vaccines Mechanism
- 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
- 2.4 Peptide Cancer Vaccine Mechanism
- 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. GLOBAL CANCER VACCINE MARKET OVERVIEW

- 3.1 Current Market Scenario
- 3.2 Future Market Opportunity

4. GLOBAL CANCER VACCINE MARKET TRENDS BY COUNTRY

- 4.1 US
- 4.2 Europe
- 4.3 China
- 4.4 Japan
- 4.5 India
- 4.6 South Korea
- 4.7 Australia
- 4.8 South America
- 4.9 Canada
- 4.10 UK

5. CANCER VACCINE MARKET INSIGHT & PROPRIETARY VACCINE MANUFACTURING TECHNOLOGIES BY INDICATION

- 5.1 Lung Cancer
 - 5.1.1 Current Clinical Market Trends
 - 5.1.2 Proprietary Manufacturing Technology Platforms
- 5.2 Pancreatic Cancer
 - 5.2.1 Current Clinical Market Trends
 - 5.2.2 Proprietary Manufacturing Technology Platforms

5.3 Prostate Cancer

5.3.1 Current Clinical Market Trends

5.3.2 Proprietary Manufacturing Technology Platforms

5.4 Bladder Cancer

5.4.1 Current Clinical Market Trends

5.4.2 Proprietary Manufacturing Technology Platforms

5.5 Melanoma

5.5.1 Current Clinical Market Trends

5.5.2 Proprietary Manufacturing Technology Platforms

5.6 Breast Cancer

5.6.1 Current Clinical Market Trends

5.6.2 Proprietary Manufacturing Technology Platforms

5.7 Colorectal Cancer

5.7.1 Current Clinical Market Trends

5.7.2 Proprietary Manufacturing Technology Platforms

5.8 Glioblastoma

5.8.1 Current Clinical Market Trends

5.8.2 Proprietary Manufacturing Technology Platforms

5.9 Ovarian Cancer

5.9.1 Current Clinical Market Trends

5.9.2 Proprietary Manufacturing Technology Platforms

5.10 Human papillomavirus Associated Cancer

5.10.1 Current Clinical Market Trends

6. APPROVED CANCER VACCINES – PRICE & DOSAGE ANALYSIS

6.1 Gardasil/ Gardasil

6.2 Cervarix

6.3 Heplisav-B

6.4 PreHevbrio

6.5 Engerix-B

6.6 Twinrix

6.7 Recombivax HB

6.8 Provenge

6.9 Cecolin

6.10 CimaVax

6.11 Vaxira

6.12 Riavax

6.13 Oncophage

6.14 Mycidac-C

6.15 Reniale

6.16 Cervavac*

7. GLOBAL CANCER VACCINES CLINICAL TRIALS OVERVIEW

7.1 By Company

7.2 By Country

7.3 By Indication

7.4 By Patient Segment/Disease Stage

7.5 By Phase

8. GLOBAL CANCER VACCINES CLINICAL TRIALS BY COMPANY, COUNTRY, INDICATION & PHASE

8.1 Research

8.2 Preclinical

8.3 Phase-I

8.4 Phase-I/II

8.5 Phase-II

8.6 Phase-II/III

8.7 Phase-III

8.8 Registered

9. MARKETED CANCER VACCINES CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION

10. COMPETITIVE LANDSCAPE

10.1 Ayala Pharmaceuticals

10.2 BioNTech

10.3 CureVac

10.4 Elicio Therapeutics

10.5 Enochian BioSciences

10.6 Enterome

10.7 EpiThany

10.8 Gradalis

10.9 Hookipa Pharma

10.10 Immunitor

- 10.11 Immunomic Therapeutics
- 10.12 In3Bio
- 10.13 IO Biotech
- 10.14 ISA Pharmaceuticals
- 10.15 Jiangsu Recbio Technology
- 10.16 Mary Crowley Cancer Research Center
- 10.17 Mayo Clinic
- 10.18 Memorial Sloan-Kettering Cancer Center
- 10.19 Mendus
- 10.20 Merck
- 10.21 MGFB Bio
- 10.22 Nykode Therapeutics
- 10.23 OncoTherapy Science
- 10.24 pHion Therapeutics
- 10.25 Qu Biologics
- 10.26 Scancell
- 10.27 UbiVac
- 10.28 Vaccitech
- 10.29 VAXIMM
- 10.30 Zhongsheng Kangyuan Biotechnology

List Of Figures

LIST OF FIGURES

Figure 1-1: Categorization & Function of Cancer Vaccines

Figure 2-1: Classification of Different Types of Cancer vaccines

Figure 3-1: Global – Cancer Vaccine Market Opportunity (US\$ Billion), 2023 - 2029

Figure 3-2: Countries Leading In Clinical Trials for Cancer Vaccines

Figure 4-1: US – Cancer Vaccine Market Opportunity (US\$ Million), 2023 - 2029

Figure 4-2: Europe – Cancer Vaccine Market Opportunity (US\$ Million), 2023 - 2029

Figure 4-3: China – Cancer Vaccine Market Opportunity (US\$ Million), 2023 - 2029

Figure 4-4: Japan – Cancer Vaccine Market Opportunity (US\$ Million), 2023 - 2029

Figure 4-5: India – Cancer Vaccine Market Opportunity (US\$ Million), 2023 - 2029

Figure 4-6: South Korea – Cancer Cases & Deaths, 2020

Figure 4-7: South Korea – Cancer Vaccine Market Opportunity (US\$ Million), 2023 - 2029

Figure 4-8: Australia – Cancer Cases & Deaths, 2020

Figure 4-9: Australia – Pricing for Non-Scheduled NIP HBV & HPV Vaccines (US\$), 2023

Figure 4-10: Australia – Cancer Vaccine Market Opportunity (US\$ Million), 2023 – 2029

Figure 4-11: Canada – Cancer Vaccine Market Opportunity (US\$ Million), 2023 - 2029

Figure 4-12: CERVARIX - Canada Patents Numbers Approval & Expiration Dates

Figure 4-13: GARDASIL-9 - Canada Patents Numbers Approval & Expiration Dates

Figure 4-14: UK – Cancer Vaccine Market Opportunity (US\$ Million), 2023 - 2029

Figure 5-1: Global – Lung Cancer Incidence & Deaths, 2020

Figure 5-2: Global – Lung Cancer Vaccine Market Opportunity (US\$ Million), 2023 – 2029

Figure 5-3: Elicio Therapeutics – AMP Platform

Figure 5-4: Global – Pancreatic Cancer Incidence & Deaths, 2020

Figure 5-5: Global – Pancreatic Cancer Vaccine Market Opportunity (US\$ Million), 2023 - 2029

Figure 5-6: Global – Prostate Cancer Incidence Among Other cancers, 2020

Figure 5-7: Global – Prostate Cancer Vaccine Market Opportunity (US\$ Million), 2023 - 2029

Figure 5-8: The UV1 Vaccine Technology

Figure 5-9: Oxford Vacmedix - Recombinant Overlapping Peptides

Figure 5-10: General Scheme of Process Development & TAPCells Treatment

Figure 5-11: Global – Bladder Cancer Incidence & Death, 2020

Figure 5-12: Global – Bladder Cancer Vaccine Market Opportunity (US\$ Million), 2023 -

2029

Figure 5-13: Lerapolturev – Mechanism of Action

Figure 5-14: Lerapolturev - Activation of APCs & Stimulating Anti Cancer Response

Figure 5-15: T-Win Vaccines – Mechanism of Action

Figure 5-16: Global – Melanoma Incidence & Death, 2020

Figure 5-17: Global – Melanoma Cancer Vaccine Market Opportunity (US\$ Million), 2025 - 2029

Figure 5-18: PIONEER – Designing Personalized Cancer Immunotherapy Vaccines

Figure 5-19: Seviprotimut-L – Mechanism of Action

Figure 5-20: Global – Breast Cancer Incidence & Death, 2020

Figure 5-21: Global – Breast Cancer Vaccine Market Opportunity (US\$ Million), 2024 - 2029

Figure 5-22: VLP Technology Platform

Figure 5-23: Global – Colorectal Cancer Incidence & Death, 2020

Figure 5-24: Global – Colorectal Cancer Vaccine Market Opportunity (US\$ Million), 2025 - 2029

Figure 5-25: BioNTech – iNeST Platform

Figure 5-26: Global – Brain Cancer Incidence & Deaths, 2020

Figure 5-27: Global – Glioblastoma Vaccine Market Opportunity (US\$ Million), 2025 – 2029

Figure 5-28: Invax - Goldspire Platform

Figure 5-29: Goldspire Platform - Antigen Signature Preparation

Figure 5-30: Goldspire Platform - Immune System Training

Figure 5-31: Enterome – OncoMimics Technology Platform

Figure 5-32: UNITE – Mode of Action

Figure 5-33: VBI Vaccines – eVLP Benefits & Structure

Figure 5-34: Global – Ovarian Cancer Incidence & Death, 2020

Figure 5-35: Global – Ovarian Cancer Vaccine Market Opportunity (US\$ Million), 2025 - 2029

Figure 5-36: Vididencel – Mode of Action

Figure 5-37: Global – Cancer Caused By High-Risk HPVs

Figure 5-38: Global – HPV Associated Cancer Incidence & Deaths, 2020

Figure 5-39: Global – HPV Vaccine Market Opportunity (US\$ Billion), 2023 - 2029

Figure 6-1: Gardasil – Approval Year by Region

Figure 6-2: Gardasil 9 – Approval Year by Region

Figure 6-3: US – Gardasil Approval Year by Indication

Figure 6-4: Canada – Gardasil Approval Year by Indication

Figure 6-5: Gardasil 9 – Patent Expiration Year by Region

Figure 6-6: US – Cost of 5ml & Per Unit Cost of Gardasil 9 Intramuscular Suspension

(US\$), May'2023

Figure 6-7: UK – Per Unit Cost of Gardasil & Gardasil 9 Injection (GBP/US\$), May'2023

Figure 6-8: Global – Gardasil/ Gardasil 9 Sales Value (US\$ Million), 2019-2023

Figure 6-9: Global – Gardasil/ Gardasil 9 Quarterly Sales Value (US\$ Million), 2022

Figure 6-10: Cervarix – Approval Year by Region

Figure 6-11: South Korea – Per Unit Cost of Cervarix Injection (KRW/US\$), July'2022

Figure 6-12: Global – Cervarix Sales Value (US\$ Million), 2019-2023

Figure 6-13: Global – Cervarix Quarterly Sales Value (US\$ Million), 2022

Figure 6-14: Regional - Cervarix Annual Sales Value (US\$ Million), 2022

Figure 6-15: Regional - Cervarix Annual Sales Value (%), 2022

Figure 6-16: Regional - Cervarix Quarterly Sales Value (US\$ Million), 2022

Figure 6-17: Heplisav-B – Approval Years by Region

Figure 6-18: US – Cost of 2.5ml & Per Unit Cost of Heplisav-B Intramuscular Suspension (US\$), May'2023

Figure 6-19: Global – Heplisav-B Sales Value (US\$ Million), 2019-2023

Figure 6-20: Global – Heplisav-B Quarterly Sales Value (US\$ Million), 2022

Figure 6-21: PreHevbrio – Approval Years by Region

Figure 6-22: US – Cost of 10 Vials & Per Unit Cost of PreHevbrio Intramuscular Suspension (US\$), May'2023

Figure 6-23: PreHevbrio – Cost of One Cycle & Full Treatment (US\$), May'2023

Figure 6-24: US – Cost of 10 Vials & Per Unit Cost of Engerix-B Intramuscular Suspension (US\$), May'2023

Figure 6-25: Twinrix – Approval Years by Region

Figure 6-26: US – Cost of 10 Vials & Per Unit Cost of Twinrix Intramuscular Suspension (US\$), May'2023

Figure 6-27: Twinrix – Cost of Standard & Accelerated Dosing (US\$), May'2023

Figure 6-28: US – Cost of 10 Vials & Per Unit Cost of Recombivax HB Intramuscular Suspension (US\$), May'2023

Figure 6-29: US – Cost of 250ml & Per Unit Cost of Provenge Intravenous Suspension (US\$), May'2023

Figure 6-30: India – Per Unit Cost of Mycidac-C Injection (INR/US\$), May'2022

Figure 7-1: Global - Number of Cancer Vaccines in Clinical Trials by Company, 2023 - 2029

Figure 7-2: Global - Number of Cancer Vaccines in Clinical Trials by Country, 2023 - 2029

Figure 7-3: Global - Number of Cancer Vaccines in Clinical Trials by Indication, 2023 - 2029

Figure 7-4: Global - Number of Cancer Vaccines Clinical Trials by Disease Stage, 2023 - 2029

Figure 7-5: Global - Number of Cancer Vaccines in Clinical Trials by Phase, 2023 – 2029

List Of Tables

LIST OF TABLES

Figure 4-1: US - Ongoing Cancer Vaccines Clinical Trials

Figure 4-2: EMA - Approved Cancer Vaccines

Figure 4-3: Europe - Cancer Vaccines Currently Under Clinical Trial

Figure 4-4: China – NMPA Approved Human Papillomavirus Vaccines

Figure 4-5: Japan - Merck Held Clinical Trials

Figure 4-6: South Korea – Ongoing Cancer Vaccines Clinical Trials

Figure 4-7: Australia – TGA Approved Hepatitis-B Vaccines

Figure 4-8: Australia – TGA Approved Human Papillomavirus Vaccines

Figure 4-9: Australia – Ongoing Melanoma Vaccines Clinical Trials

Figure 4-10: South America - Cancer Vaccines Currently Under Clinical Trial

Figure 4-11: Canada - Approved Cancer Vaccines

Figure 4-12: Canada - Cancer Vaccines Currently Under Clinical Trial

Figure 4-13: UK - Approved Cancer Vaccines

Figure 4-14: UK - Cancer Vaccines Currently Under Clinical Trial

I would like to order

Product name: Global Cancer Vaccine Marke, Vaccine Price, Dosage, Sales & Clinical Trials Outlook 2029

Product link: <https://marketpublishers.com/r/GEAD47ED7499EN.html>

Price: US\$ 3,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEAD47ED7499EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

